FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011914976> ?p ?o ?g. }

• W2011914976 endingPage "58" @default.
• W2011914976 startingPage "52" @default.
• W2011914976 abstract "Background. The response of spider leg veins to laser or intense pulsed light therapy has generally been characterized by varying degrees of success and frequently inconsistent clinical response rates. Objective. The purpose of this study was to examine the effectiveness of the 755 nm long pulsed infrared alexandrite (LPA) laser for the treatment of leg telangiectasias. Methods. This study was constructed in four phases. Phase I examined 28 patients with variable sized telangiectasias using 5 treatment parameters (15 J/cm2× 1 pulse, 20 J/cm2× 1 pulse, 20 J/cm2× 2 pulses, 20 J/cm2× 3 pulses, or 30 J/cm2× 1 pulse). Each patient received 3 treatments at 4 week intervals with the LPA. Patient diaries were obtained to examine the effects of the treatments. Subjective grading was performed at each follow-up visit by the investigators. Blinded objective grading was performed at the conclusion of the study by trained observers. Phase II examined the effects of these treatment parameters on varying vessel diameters. Vessels were grouped into small (<0.4 mm), intermediate (0.4-1.0 mm), and large (1.0-3.0 mm) subsets. Phase III examined the effects of a combination of LPA treatment followed by 23.4% hypertonic saline sclerotherapy. Subjective and blinded objective grading was used to determine improvement after a single treatment with the LPA at 20 J/cm2, single pulsed with a pulse duration of 5 or 10 msec followed by treatment with 23.4% hypertonic saline injected 3, 7, 14, or 28 days after laser therapy. Phase IV involved biopsies after LPA treatment alone at time intervals of immediately posttreatment and 5 and 21 days posttreatment. Results. These evaluations revealed that the optimal treatment parameters for LPA therapy alone appeared to be 20 J/cm2, double pulsed at a repetition rate of one Hz. After 3 treatments at 4 week intervals, subjective grading indicated a 63% reduction in leg telangiectasias. Medium diameter vessels responded best with small vessel diameters responding poorly, if at all. The addition of 23.4% hypertonic saline sclerotherapy performed 3 to 7 days after laser therapy (LPA at 20 J/cm2, single pulsed with a pulse duration of 5 msec) produced 87% reduction in leg telangiectasias. Biopsies after LPA treatment revealed vessel wall endothelial cell necrosis at 5 days with fibrosis occurring at 3 weeks. The optimal clinical “window” for sclerotherapy seems to coincide with the period of endothelial cell necrosis. Conclusion. LPA therapy is most effective for leg telangiectasias 0.4-3.0mm in diameter. This LPA technique is significantly improved with the addition of sclerotherapy." @default.
• W2011914976 created "2016-06-24" @default.
• W2011914976 creator A5003184744 @default.
• W2011914976 creator A5050061967 @default.
• W2011914976 creator A5068321158 @default.
• W2011914976 creator A5068485193 @default.
• W2011914976 creator A5082039449 @default.
• W2011914976 creator A5089445903 @default.
• W2011914976 date "1999-01-01" @default.
• W2011914976 modified "2023-10-15" @default.
• W2011914976 title "Laser Therapy of Spider Leg Veins: Clinical Evaluation of a New Long Pulsed Alexandrite Laser" @default.
• W2011914976 cites W1574848434 @default.
• W2011914976 cites W1980725772 @default.
• W2011914976 cites W1986409293 @default.
• W2011914976 cites W1987210883 @default.
• W2011914976 cites W2008011814 @default.
• W2011914976 cites W2011745269 @default.
• W2011914976 cites W2015274489 @default.
• W2011914976 cites W2015818399 @default.
• W2011914976 cites W2027391306 @default.
• W2011914976 cites W2032711516 @default.
• W2011914976 cites W2042349869 @default.
• W2011914976 cites W2055036751 @default.
• W2011914976 cites W2070000027 @default.
• W2011914976 cites W2096694474 @default.
• W2011914976 cites W2103644528 @default.
• W2011914976 cites W2142809883 @default.
• W2011914976 cites W2149187521 @default.
• W2011914976 cites W2418609259 @default.
• W2011914976 cites W29285311 @default.
• W2011914976 cites W4233994136 @default.
• W2011914976 doi "https://doi.org/10.1046/j.1524-4725.1999.08117.x" @default.
• W2011914976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9935096" @default.
• W2011914976 hasPublicationYear "1999" @default.
• W2011914976 type Work @default.
• W2011914976 sameAs 2011914976 @default.
• W2011914976 citedByCount "94" @default.
• W2011914976 countsByYear W20119149762012 @default.
• W2011914976 countsByYear W20119149762013 @default.
• W2011914976 countsByYear W20119149762014 @default.
• W2011914976 countsByYear W20119149762015 @default.
• W2011914976 countsByYear W20119149762016 @default.
• W2011914976 countsByYear W20119149762017 @default.
• W2011914976 countsByYear W20119149762018 @default.
• W2011914976 countsByYear W20119149762019 @default.
• W2011914976 countsByYear W20119149762020 @default.
• W2011914976 countsByYear W20119149762021 @default.
• W2011914976 crossrefType "journal-article" @default.
• W2011914976 hasAuthorship W2011914976A5003184744 @default.
• W2011914976 hasAuthorship W2011914976A5050061967 @default.
• W2011914976 hasAuthorship W2011914976A5068321158 @default.
• W2011914976 hasAuthorship W2011914976A5068485193 @default.
• W2011914976 hasAuthorship W2011914976A5082039449 @default.
• W2011914976 hasAuthorship W2011914976A5089445903 @default.
• W2011914976 hasConcept C120665830 @default.
• W2011914976 hasConcept C121332964 @default.
• W2011914976 hasConcept C126322002 @default.
• W2011914976 hasConcept C127413603 @default.
• W2011914976 hasConcept C141071460 @default.
• W2011914976 hasConcept C147176958 @default.
• W2011914976 hasConcept C2776330896 @default.
• W2011914976 hasConcept C2777286243 @default.
• W2011914976 hasConcept C2777397205 @default.
• W2011914976 hasConcept C2778230777 @default.
• W2011914976 hasConcept C2780167933 @default.
• W2011914976 hasConcept C2989005 @default.
• W2011914976 hasConcept C3017567848 @default.
• W2011914976 hasConcept C520434653 @default.
• W2011914976 hasConcept C71924100 @default.
• W2011914976 hasConcept C94915269 @default.
• W2011914976 hasConceptScore W2011914976C120665830 @default.
• W2011914976 hasConceptScore W2011914976C121332964 @default.
• W2011914976 hasConceptScore W2011914976C126322002 @default.
• W2011914976 hasConceptScore W2011914976C127413603 @default.
• W2011914976 hasConceptScore W2011914976C141071460 @default.
• W2011914976 hasConceptScore W2011914976C147176958 @default.
• W2011914976 hasConceptScore W2011914976C2776330896 @default.
• W2011914976 hasConceptScore W2011914976C2777286243 @default.
• W2011914976 hasConceptScore W2011914976C2777397205 @default.
• W2011914976 hasConceptScore W2011914976C2778230777 @default.
• W2011914976 hasConceptScore W2011914976C2780167933 @default.
• W2011914976 hasConceptScore W2011914976C2989005 @default.
• W2011914976 hasConceptScore W2011914976C3017567848 @default.
• W2011914976 hasConceptScore W2011914976C520434653 @default.
• W2011914976 hasConceptScore W2011914976C71924100 @default.
• W2011914976 hasConceptScore W2011914976C94915269 @default.
• W2011914976 hasIssue "1" @default.
• W2011914976 hasLocation W20119149761 @default.
• W2011914976 hasLocation W20119149762 @default.
• W2011914976 hasOpenAccess W2011914976 @default.
• W2011914976 hasPrimaryLocation W20119149761 @default.
• W2011914976 hasRelatedWork W130622536 @default.
• W2011914976 hasRelatedWork W1554315021 @default.
• W2011914976 hasRelatedWork W1979131142 @default.
• W2011914976 hasRelatedWork W2025966574 @default.
• W2011914976 hasRelatedWork W2094999320 @default.
• W2011914976 hasRelatedWork W2152329171 @default.
• W2011914976 hasRelatedWork W2509338288 @default.

• next